secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0001558370-23-015838
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios Therapeutics terminates at-the-market sales agreement with JonesTrading
------------------------------------------------------------------------------

- Sales agreement terminated effective Sept 28, 2023; no sales since Aug 9, 2023; up to $6.7M capacity.
- Company faces no termination penalties.
- Focus shifts to operational priorities: second Long-COVID study of IMC-2, non-dilutive funding, FDA meeting.
- CEO Greg Duncan cites current market conditions as rationale.
- Pre-IND meeting planned with FDA for IMC-2 in Long-COVID and fatigue disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023015838/0001558370-23-015838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023015838/tmb-20230918x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer